Stocklytics Platform
Asset logo for symbol VRCA
Verrica Pharmaceuticals
VRCA56
$0.67arrow_drop_down1.82%-$0.01
Penny Stock
Asset logo for symbol VRCA
VRCA56

$0.67

arrow_drop_down1.82%
Key Stats
Open$0.66
Prev. Close$0.68
EPS-1.84
DividendNon-Dividend
Next Earnings Date-
Dividend Yield %-
Market Cap$61.91M
PE Ratio-
LOWHIGH
Day Range0.66
0.68
52 Week Range0.61
11.41
Ratios
EPS-1.84
Fundamentals
Debt/Equity Ratio-
Payout Ratio-
Industry average yield3.08%
Last Dividend pay date-
Dividend per share-
Dividend yield forecast-

Stock Analysis

Technicals

Summarizing what the indicators are suggesting.

Strong Buy
Buy
Neutral
Sell
Strong Sell

Analyst rating

An aggregate view of professional's ratings.

Strong Buy
Buy
Neutral
Sell
Strong Sell

Stock Performance

VRCA-
US Healthcare Sector-
US Market-
warning

VRCA / Market

VRCA lose to the US Market which returned -0.26% over the last twenty four hours.
warning

VRCA / Healthcare Sector

VRCA lose to the US Healthcare sector which returned 1.31% over the last twenty four hours.

Verrica Pharmaceuticals (VRCA) Statistics

Verrica Pharmaceuticals Inc (VRCA) is a biopharmaceutical company focused on the development and commercialization of innovative therapies for skin diseases. The company's lead product candidate, VP-102, is a drug-device combination therapy designed for the treatment of molluscum contagiosum, a common and highly contagious viral skin infection. Verrica has conducted extensive clinical trials to evaluate the safety and efficacy of VP-102, and the results have been promising. The company is currently awaiting approval from the U.S. Food and Drug Administration (FDA) for the marketing of VP-102.
In terms of valuation metrics, Verrica Pharmaceuticals Inc has a market capitalization of approximately $300 million, based on the current stock price. The company's stock has shown strong performance compared to the broader sector, with a significant increase in value over the past year. This indicates positive investor sentiment and confidence in the company's growth prospects. Verrica Pharmaceuticals Inc has also demonstrated solid fundamentals, with a healthy profit margin and a low level of total debt. The company's revenue per share is an important indicator of its financial performance, and it is expected to increase as VP-102 gains market traction. Additionally, Verrica Pharmaceuticals Inc has a strong gross profit, reflecting the company's ability to generate revenue from its products.
add Verrica Pharmaceuticals  to watchlist

Keep an eye on Verrica Pharmaceuticals

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

Frequently Asked Questions

search
help

How has Verrica Pharmaceuticals (VRCA) stock's performance compared to its sector and the market over the past year?

Over the past year, Verrica Pharmaceuticals (VRCA) has experienced a price change of . Compared to the Healthcare sector, which saw a change of 20.69%, Verrica Pharmaceuticals has underperformed compared to its sector, indicating its relative standing within the Healthcare sector. Against the broader market's change of 44.15%, it has fallen short of the market average. This comparison highlights Verrica Pharmaceuticals 's performance relative to both its sector and the overall market over the last year.
help

What is the PE ratio of Verrica Pharmaceuticals (VRCA) stock?

The PE ratio for Verrica Pharmaceuticals (VRCA) is currently not available. This could be due to a variety of factors such as the company not having positive earnings at the moment or recent updates not being reflected.
help

What is the EPS of Verrica Pharmaceuticals (VRCA) stock?

The Earnings Per Share (EPS) for Verrica Pharmaceuticals (VRCA), calculated on a diluted basis, is -$1.84. EPS is a key indicator of a company's profitability, showing the portion of a company's profit allocated to each outstanding share of common stock.
help

What is the operating margin of Verrica Pharmaceuticals (VRCA) stock?

The operating margin for Verrica Pharmaceuticals (VRCA) is 1.16K%. This metric represents the percentage of revenue that remains after paying for variable production costs, indicating the efficiency and profitability of the company's core business operations.
help

What is the EBITDA of Verrica Pharmaceuticals (VRCA) stock?

The EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) of Verrica Pharmaceuticals (VRCA) is -$73.39M. EBITDA is a widely used earnings metric to assess a company's operational efficiency and profitability before the impact of non-operating decisions such as financing, accounting, and tax environments.
help

How much debt does Verrica Pharmaceuticals (VRCA) have?

Verrica Pharmaceuticals (VRCA) has a total debt of $47.11M. The net debt, which accounts for cash and cash equivalents against the total debt, is $24.15M.

Take Your Investments to a Whole New Level